| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 27/02/2025 | 22:13 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:CSTL | Castle Biosciences Inc |
| 27/02/2025 | 22:07 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CSTL | Castle Biosciences Inc |
| 27/02/2025 | 22:05 | Business Wire | Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results | NASDAQ:CSTL | Castle Biosciences Inc |
| 25/02/2025 | 22:30 | Business Wire | Castle Biosciences to Participate in Upcoming Investor Conferences | NASDAQ:CSTL | Castle Biosciences Inc |
| 24/02/2025 | 22:23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CSTL | Castle Biosciences Inc |
| 12/02/2025 | 22:30 | Business Wire | Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® | NASDAQ:CSTL | Castle Biosciences Inc |
| 06/02/2025 | 13:00 | Business Wire | Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 | NASDAQ:CSTL | Castle Biosciences Inc |
| 17/01/2025 | 13:00 | Business Wire | Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 | NASDAQ:CSTL | Castle Biosciences Inc |
| 13/01/2025 | 00:00 | Business Wire | Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results | NASDAQ:CSTL | Castle Biosciences Inc |
| 06/01/2025 | 22:29 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CSTL | Castle Biosciences Inc |
| 06/01/2025 | 13:00 | Business Wire | Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test | NASDAQ:CSTL | Castle Biosciences Inc |
| 23/12/2024 | 13:00 | Business Wire | Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test | NASDAQ:CSTL | Castle Biosciences Inc |
| 19/12/2024 | 13:00 | Business Wire | Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:CSTL | Castle Biosciences Inc |
| 12/12/2024 | 13:00 | Business Wire | Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma | NASDAQ:CSTL | Castle Biosciences Inc |
| 20/11/2024 | 13:00 | Business Wire | Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference | NASDAQ:CSTL | Castle Biosciences Inc |
| 19/11/2024 | 13:00 | Business Wire | Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year | NASDAQ:CSTL | Castle Biosciences Inc |
| 08/11/2024 | 13:00 | Business Wire | Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting | NASDAQ:CSTL | Castle Biosciences Inc |
| 07/11/2024 | 13:00 | Business Wire | Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test | NASDAQ:CSTL | Castle Biosciences Inc |
| 06/11/2024 | 13:00 | Business Wire | Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 | NASDAQ:CSTL | Castle Biosciences Inc |
| 04/11/2024 | 22:11 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CSTL | Castle Biosciences Inc |
| 04/11/2024 | 22:05 | Business Wire | Castle Biosciences Reports Third Quarter 2024 Results | NASDAQ:CSTL | Castle Biosciences Inc |
| 29/10/2024 | 21:30 | Business Wire | Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients | NASDAQ:CSTL | Castle Biosciences Inc |
| 20/10/2024 | 11:00 | Business Wire | Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors | NASDAQ:CSTL | Castle Biosciences Inc |
| 16/10/2024 | 13:00 | Business Wire | Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential | NASDAQ:CSTL | Castle Biosciences Inc |
| 14/10/2024 | 13:00 | Business Wire | Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 | NASDAQ:CSTL | Castle Biosciences Inc |
| 11/10/2024 | 13:00 | Business Wire | Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin | NASDAQ:CSTL | Castle Biosciences Inc |
| 09/10/2024 | 13:00 | Business Wire | New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions | NASDAQ:CSTL | Castle Biosciences Inc |
| 02/10/2024 | 13:00 | Business Wire | Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas | NASDAQ:CSTL | Castle Biosciences Inc |
| 27/09/2024 | 23:15 | Business Wire | New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | NASDAQ:CSTL | Castle Biosciences Inc |
| 23/09/2024 | 13:00 | Business Wire | New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus | NASDAQ:CSTL | Castle Biosciences Inc |
